Michael Roundy
Psychiatry · Bountiful, UTNPI 1255366696
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 39.1% of the total. Reporting peaked in 2024 at $968 and has fallen 81.9% since, to $175 in 2025. Among psychiatry clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $12.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$598
- Vanda Pharmaceuticals Inc.$380
- Otsuka America Pharmaceutical, Inc.$375
- Indivior Inc.$241
- Neurocrine Biosciences, Inc.$177
- plus $693 from 11 others
Across 313 payments — averaging $7845.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$2.2M
- Janssen Research & Development, LLC$223K
- Eli Lilly$10K
What the payments were for
- Food & beverage$4,046100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,046 in reported general payments places this provider in the 90th percentile of 231 psychiatry providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 14 | $38,073 |
| Invega SustennaPaliperidone Palmitate | 13 | $29,577 |
| FanaptIloperidone | 13 | $21,862 |
| Lurasidone Hcl | 42 | $5,358 |
| Lisdexamfetamine Dimesylate | 24 | $5,209 |
| Aripiprazole | 46 | $2,791 |
| Olanzapine | 57 | $1,846 |
| Bupropion XlBupropion Hcl | 51 | $1,498 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $1,359 |
| Duloxetine Hcl | 82 | $1,305 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 27 | $1,305 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 44 | $1,277 |
| Lamotrigine | 94 | $904 |
| Ziprasidone Hcl | 20 | $863 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $375 | $38,07314 claims |
| Johnson & JohnsonInvega Sustenna | $126 | $29,57713 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $380 | $21,86213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 231 psychiatry providers in Utah.
Other psychiatry in Bountiful
- Oliver McPhersonBountiful$20K
- Carmela JavellanaBountiful$2K
- Nancy PantzirisBountiful$497
- Michael MeasomSlc$2.2M
- Noel GardnerSalt Lake City$512K
- Reid RobisonOrem$133K
- Thomas RaynerProvo$60K
- Trent HolmbergDraper$32K
- Nathan CurrierRiverton$21K
- Frederick ReimherrSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.